



EARNINGS RELEASE FINANCIAL SUPPLEMENT

FIRST QUARTER 2021

Q1 2021 Financial Statements	
Consolidated Statements of Operations	1
Consolidated Balance Sheets	2
Consolidated Statements of Cash Flows	3
Historical Financial Statements	
Consolidated Statements of Operations (2019 & 2020 Quarterly)	4
Consolidated Balance Sheets (2020 Quarterly)	5
Consolidated Statements of Cash Flows (2020 Quarterly)	6
Reconciliations of Non-GAAP to GAAP financial measures	
Adjusted EBITDA (Q1 2021 and Trailing Twelve Month)	7
Adjusted Net Income and Adjusted EPS	9
Free Cash Flow	9
Net Debt	10
Adjusted EBITDA, Adjusted Net Income and Adjusted EPS Footnotes	11
Historical Reconciliations of Non-GAAP to GAAP financial measures	
Adjusted EBITDA	12

Q1 2021 FINANCIAL STATEMENTS

PETCO HEALTH AND WELLNESS COMPANY, INC. CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

(In Thousands, except per share amounts) (Unaudited and subject to reclassification)

		13 Weeks Ended					
	May 1, 2021			May 2, 2020	Percent Change		
Net sales	\$1,	414,994	\$ 1	,113,521	27%		
Cost of sales		818,009		647,239	26%		
Gross profit		596,985		466,282	28%		
Selling, general and administrative expenses		549,236		449,917	22%		
Operating income		47,749		16,365	192%		
nterest income		(21)		(184)	(89%)		
nterest expense		20,529		60,808	(66%)		
Loss on extinguishment and modification of debt		20,838		_	N/M		
Income (loss) before income taxes and income from							
equity method investees		6,403		(44,259)	N/M		
ncome tax expense (benefit)		2,679		(10,555)	N/M		
ncome from equity method investees		(2,425)		(332)	630%		
Net income (loss)		6,149		(33,372)	N/M		
Net loss attributable to noncontrolling interest		(1,411)		(2,204)	(36%)		
Net income (loss) attributable to Class A and B-1 common							
stockholders	\$	7,560	\$	(31,168)	N/M		
Net income (loca) per Class A and B 1 common share							
Net income (loss) per Class A and B-1 common share: Basic	\$	0.03	¢	(0.15)	N/M		
Diluted	,		\$	(0.15)			
Diluted	\$	0.03	\$	(0.15)	N/M		
Neighted average shares used in computing net income (loss) per Class A and B-1 common share:							
Basic		264,215		209,015	26%		
Diluted		265,028		209,015	27%		

PETCO HEALTH AND WELLNESS COMPANY, INC. CONSOLIDATED BALANCE SHEETS

(In Thousands, except per share amounts) (Unaudited and subject to reclassification)

	May 1, 2021		January 30, 2021		
ASSETS					
Current assets:					
Cash and cash equivalents	\$	174,034	\$	111,402	
Receivables, less allowance for credit losses ¹		38,079		41,827	
Merchandise inventories, net		574,683		538,675	
Prepaid expenses		46,724		40,032	
Other current assets		42,355		45,613	
Total current assets		875,875		777,549	
Fixed assets		1,535,617		1,487,987	
Less accumulated depreciation		(896,195)		(860,440)	
Fixed assets, net		639,422		627,547	
Operating lease right-of-use assets		1,330,816		1,328,108	
Goodwill		2,179,310		2,179,310	
Trade name		1,025,000		1,025,000	
Other intangible assets		4,793		4,793	
Less accumulated amortization		(4,164)	_	(4,079)	
Other intangible assets, net		629		714	
Other long-term assets		142,347		137,474	
Total assets	\$	6,193,399	\$	6,075,702	
LIABILITIES AND EQUITY					
Current liabilities:					
Accounts payable and book overdrafts	\$	352,401	\$	339,485	
Accrued salaries and employee benefits		127,000		129,484	
Accrued expenses and other liabilities		218,926		145,846	
Current portion of operating lease liabilities		276,619		258,289	
Current portion of long-term debt and other lease liabilities		20,234		2,203	
Total current liabilities		995,180		875,307	
Senior secured credit facilities, net, excluding current portion		1,649,509		1,646,281	
Operating lease liabilities, excluding current portion		1,056,059		1,083,575	
Deferred taxes, net		282,350		280,920	
Other long-term liabilities		138,069		134,354	
Total liabilities		4,121,167		4,020,437	
Commitments and contingencies					
Stockholders' equity:					
Class A common stock ²		226		226	
Class B-1 common stock ³		38		38	
Class B-2 common stock ⁴		_		_	
Preferred stock ⁵		_		_	
Additional paid-in-capital		2,103,714		2,092,110	
Accumulated deficit		(14,691)		(22,251)	
Accumulated other comprehensive loss		(2,061)		(1,275)	
Total stockholders' equity		2,087,226		2,068,848	
Noncontrolling interest		(14,994)		(13,583)	
Total equity		2,072,232		2,055,265	
Total liabilities and equity	\$	6,193,399	\$	6,075,702	
rotar nubintion and oquity	Ψ	0,100,000	Ψ	0,010,102	

(1) Allowances for credit losses are \$2,217 as of May 1, 2021 and \$3,267 as of Jan 30, 2021

(2) Class A common stock, par value \$0.001 per share (1.0 billion shares authorized and 226.5 million shares issued and outstanding as of May 1, 2021 and 226.4 million shares issued and outstanding as of January 30, 2021)

(3) Class B-1 common stock, par value \$0.001 per share (75.0 million shares authorized and 37.8 million shares issued and outstanding)

(4) Class B-2 common stock, par value \$0.000001 per share (75.0 million shares authorized and 37.8 million shares issued and outstanding)

(5) Preferred stock, par value \$0.001 per share (25.0 million shares authorized and no shares issued or outstanding)

PETCO HEALTH AND WELLNESS COMPANY, INC. CONSOLIDATED STATEMENTS OF CASH FLOWS

(In Thousands)

(Unaudited and subject to reclassification)

	13 Week	s Ended
	May 1, 2021	May 2, 2020
Cash flows from operating activities:		
Net income (loss)	\$ 6,149	\$ (33,372)
Adjustments to reconcile net income (loss) to net cash provided by (used in) operating activities:		
Depreciation and amortization	41,607	43,567
Amortization of debt discounts and issuance costs	2,165	6,028
Provision for deferred taxes	1,708	(11,680)
Equity-based compensation	11,604	2,305
Impairments, write-offs and losses on sale of fixed and other assets	947	3,409
Loss on extinguishment and modification of debt	20,838	
Income from equity method investees	(2,425)	(332)
Amounts reclassified out of accumulated other comprehensive income	_	2,337
Change in contingent consideration obligation		(553)
Non-cash operating lease costs	105,188	108,841
Changes in assets and liabilities:		
Receivables	3,748	(3,767)
Merchandise inventories	(36,008)	(3,307)
Prepaid expenses and other assets	(9,140)	(6,302)
Accounts payable and book overdrafts	20,119	(74,074)
Accrued salaries and employee benefits	(2,483)	(10,153)
Accrued expenses and other liabilities	66,120	5,853
Operating lease liabilities	(116,994)	(64,188)
Other long-term liabilities	1,859	3,099
Net cash provided by (used in) operating activities	115,002	(32,289)
Cash flows from investing activities:		
Cash paid for fixed assets	(47,351)	(27,895)
Net cash used in investing activities	(47,351)	(27,895)
Cash flows from financing activities:	. <u> </u>	
Borrowings under long-term debt agreements	1,700,000	397,000
Repayments of long-term debt	(1,678,111)	(142,313)
Debt refinancing costs and original issue discount	(24,665)	
Payments for finance lease liabilities	(593)	(935)
Payment of offering costs	(3,844)	
Net cash (used in) provided by financing activities	(7,213)	253,752
Net increase in cash, cash equivalents and restricted cash	60,438	193,568
Cash, cash equivalents and restricted cash at beginning of period	119,540	154,718
Cash, cash equivalents and restricted cash at end of period	\$ 179,978	\$ 348,286

HISTORICAL FINANCIAL STATEMENTS

PETCO HEALTH AND WELLNESS COMPANY, INC. CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (In Thousands, except per share amounts)

(Quarters Unaudited)

				13 Week	s End	ed				scal Year Ended
		May 2, 2020	A	ugust 1, 2020		ctober 31, 2020	Ja	nuary 30, 2021	Ja	nuary 30, 2021
Net sales	\$	1,113,521	\$ 1	,208,971	\$	1,259,997	\$ 1	,337,713	\$ 4	,920,202
Cost of sales		647,239		679,218		718,559		768,448	2	,813,464
Gross profit		466,282		529,753		541,438		569,265	2	,106,738
Selling, general and administrative expenses		449,917		464,706		495,401		502,290	1	,912,314
Operating income		16,365		65,047		46,037		66,975		194,424
Interest income		(184)		(99)		(49)		(321)		(653)
Interest expense		60,808		54,493		53,795		49,987		219,083
Loss on extinguishment of debt		_		_		_		17,549		17,549
(Loss) income before income taxes and income from equity method	_									
investees		(44,259)		10,653		(7,709)		(240)		(41,555)
Income tax (benefit) expense		(10,555)		4,958		(7,940)		10,200		(3,337)
Income from equity method investees		(332)		(745)		(1,875)		(3,530)		(6,482)
Net (loss) income		(33,372)		6,440		2,106		(6,910)		(31,736)
Net loss attributable to noncontrolling interest		(2,204)		(1,001)		(1,297)		(751)		(5,253)
Net (loss) income attributable to Class A and B-1 common	\$	(31,168)	\$	7,441	\$	3,403	\$	(6,159)	\$	(26,483)
Net (loss) income per Class A and B-1 common share:										
Basic	\$	(0.15)	\$	0.04	\$	0.02	\$	(0.03)	\$	(0.13)
Diluted	\$	(0.15)	\$	0.04	\$	0.02	\$	(0.03)	\$	(0.13)
Weighted average shares used in computing net (loss) income per Class A a	nd B-1	1 common s	hare:							
Basic		209,015		209,015		209,015		215,687		210,683
Diluted		209,015		209,015		209,015		215,687		210,683

				13 Week	s End	ed				scal Year Ended
		May 4, 2019	ļ	August 3, 2019	No	vember 2, 2019	F	ebruary 1, 2020	Fe	bruary 1, 2020
Net sales	\$	1,097,157	\$	1,095,632	\$	1,093,069	\$	1,148,656	\$ 4	,434,514
Cost of sales		631,919		624,623		620,695		650,758	2	2,527,995
Gross profit		465,238	_	471,009		472,374		497,898	1	,906,519
Selling, general and administrative expenses		451,671		438,982		448,501		437,765	1	,776,919
Goodwill and indefinite-lived intangible impairment		_		_		_		19,000		19,000
Operating income		13,567	_	32,027		23,873		41,133		110,600
Interest income		(80)		(90)		(31)		(134)		(335)
Interest expense		64,472		64,600		63,150		60,796		253,018
(Loss) income before income taxes and income from equity method										
investees		(50,825)		(32,483)		(39,246)		(19,529)		(142,083)
Income tax benefit		(12,514)		(7,302)		(8,447)		(7,395)		(35,658)
(Income) loss from equity method investees		(18)		(420)		112		(2,115)		(2,441)
Net loss		(38,293)		(24,761)		(30,911)		(10,019)		(103,984)
Net loss attributable to noncontrolling interest		(812)		(1,759)		(2,692)		(2,848)		(8,111)
Net (loss) income attributable to Class A and B-1 common	\$	(37,481)	\$	(23,002)	\$	(28,219)	\$	(7,171)	\$	(95,873)
Net loss per Class A and B-1 common share:										
Basic	\$	(0.18)	\$	(0.11)	\$	(0.14)	\$	(0.03)	\$	(0.46)
Diluted	\$	(0.18)	\$	(0.11)	\$	(0.14)	\$	(0.03)	\$	(0.46)
Weighted average shares used in computing net loss per Class A and B-1 col	mmor	n share:								
Basic		208,814		208,887		209,015		209,015		208,933
Diluted		208,814		208,887		209,015		209,015		208,933

PETCO HEALTH AND WELLNESS COMPANY, INC.

CONSOLIDATED BALANCE SHEETS

(In Thousands, except per share amounts) (Audited, except for Q1 2020 ending May 2, 2020)

	May 2, 2020	August 1, 2020	October 31, 2020	January 30, 2021
ASSETS		·		
Current assets:				
Cash and cash equivalents	\$ 341,506	\$ 168,892	\$ 195,832	\$ 111,402
Receivables, less allowance for credit losses ¹	35,283	36,724	40,454	41,827
Merchandise inventories, net	482,275	489,095	541,352	538,675
Prepaid expenses	29,008	31,052	38,007	40,032
Other current assets	29,195	30,164	57,950	45,613
Total current assets	917,267	755,927	873,595	777,549
Fixed assets	1,383,680	1,402,808	1,447,294	1,487,987
Less accumulated depreciation	(752,232)	(787,946)	(828,364)	(860,440)
Fixed assets, net	631,448	614,862	618,930	627,547
Operating lease right-of-use assets	1,483,722	1,428,563	1,377,682	1,328,108
Goodwill	2,179,310	2,179,310	2,179,310	2,179,310
Trade name	1,025,000	1,025,000	1,025,000	1,025,000
Other intangible assets	4,792	4,792	4,792	4,793
Less accumulated amortization	(3,482)	(3,725)	(3,923)	(4,079)
Other intangible assets, net	1,310	1,067	869	714
Other long-term assets	116,692	120,080	128,428	137,474
Total assets	\$ 6,354,749	\$ 6,124,809	\$ 6,203,814	\$ 6,075,702
LIABILITIES AND EQUITY	¢ 0,00 i,i io	\$ 0,121,000	¢ 0,200,011	\$ 0,01 0,1 02
Current liabilities:				
Accounts payable and book overdrafts	\$ 219,129	\$ 274,232	\$ 347,789	\$ 339,485
Accrued salaries and employee benefits	\$ 219,129	98,304	129,288	129,484
Accrued expenses and other liabilities	147,737	182,342	182,502	145,846
Current portion of operating lease liabilities	313,789	275,065	246,319	258,289
Current portion of long-term debt and other lease liabilities	28,243	27,595	27,399	2,203
Total current liabilities	793,933	857,538	933,297	875,307
Senior secured credit facilities, net, excluding current portion	2,622,211	2,356,169	2,330,176	1,646,281
Senior notes, net	866,952	867,778	868,624	1,040,201
Operating lease liabilities, excluding current portion	1,189,999	1,149,642	1,127,717	1,083,575
Deferred taxes, net	252,387	243,119	272,821	280,920
Other long-term liabilities	102,567	112,922	125,562	134,354
Total liabilities	5,828,049	5,587,168	5,658,197	4,020,437
Commitments and contingencies	5,020,049	3,307,100	5,050,157	4,020,437
Stockholders' equity:				
Members' interest ²	1,360,435	1,362,643	1,365,490	
Class A common stock ³	1,300,435	1,302,043	1,303,490	226
	-	_	_	
Class B-1 common stock ⁴	_	_	_	38
Class B-2 common stock ⁵	—	—	—	—
Preferred stock ⁶	_	-	_	
Additional paid-in-capital	_	—	—	2,092,110
Accumulated deficit ²	(811,634)	(804,193)	(800,790)	(22,251)
Accumulated other comprehensive loss	(11,567)	(9,274)	(6,251)	(1,275)
Total stockholders' equity	537,234	549,176	558,449	2,068,848
Noncontrolling interest	(10,534)	(11,535)	(12,832)	(13,583)
Total equity	526,700	537,641	545,617	2,055,265
Total liabilities and equity	\$ 6,354,749	\$ 6,124,809	\$ 6,203,814	\$ 6,075,702

(1) Allowances for credit losses are \$2,110 as of May 2, 2020, \$2,099 as of August 1 2020, \$3,085 as of October 31, 2020, and \$3,267 as of January 30, 2021

(2) Balances prior to the company's conversion to a Delaware corporation were reclassified to additional paid-in capital upon conversion

- (3) Class A common stock, par value \$0.001 per share (1.0 billion shares authorized and 226.4 million shares issued and outstanding as of January 30, 2021)
- (4) Class B-1 common stock, par value \$0.001 per share (75.0 million shares authorized and 37,790,781 shares issued and outstanding as of January 30, 2021)
- (5) Class B-2 common stock, par value \$0.000001 per share (75.0 million shares authorized and 37,790,781 shares issued and outstanding as of January 30, 2021)
- (6) Preferred stock, par value \$0.001 per share (25.0 million shares authorized and no shares issued or outstanding as of January 30, 2021)

PETCO HEALTH AND WELLNESS COMPANY, INC. CONSOLIDATED STATEMENTS OF CASH FLOWS

(In thousands) (Quarters Unaudited)

					Fiscal Year Ended
	May 2,	13 Weeks Ended August 1, October 31, January 30,		October 31, January 30,	
	2020	2020	2020	2021	January 30, 2021
Cash flows from operating activities:					
Net (loss) income	\$ (33,372)	\$ 6,440	\$ 2,106	\$ (6,910)	\$ (31,736
Adjustments to reconcile net (loss) income to net cash					
(used in) provided by operating activities:					
Depreciation and amortization	43,567	42,471	42,923	45,875	174,836
Amortization of debt discounts and issuance costs	6,028	6,097	6,166	5,946	24,237
Provision for deferred taxes	(11,680)	(10,073)	28,642	18,659	25,548
Equity-based compensation	2,305	2,312	2,847	5,451	12,915
Impairments, write-offs and losses on sale of fixed and other assets	3,409	2,852	1,390	7,955	15,606
Loss on extinguishment of debt	_	_	_	17,549	17,549
Income from equity method investees	(332)	(745)	(1,875)	(3,530)	(6,482
Amounts reclassified out of accumulated other comprehensive income	2,337	2,729	2,832	2,895	10,793
Change in contingent consideration obligation	(553)	162	(34)	27	(398
Non-cash operating lease costs	108,841	107,888	107,748	105,882	430,359
Changes in assets and liabilities:					
Receivables	(3,767)	(1,441)	(3,730)	(1,373)	(10,311
Merchandise inventories	(3,307)	(7,749)	(52,257)	2,678	(60,635
Prepaid expenses and other assets	(6,302)	(2,851)	(9,498)	4,809	(13,842
Accounts payable and book overdrafts	(74,074)	55,119	73,478	(8,220)	46,303
Accrued salaries and employee benefits	(10,153)	13,269	30,984	195	34,295
Accrued expenses and other liabilities	5,853	29,894	(28,093)	(35,943)	(28,289
Operating lease liabilities	(64,188)	(132,512)	(107,726)	(95,131)	(399,557
Other long-term liabilities	3,099	10,816	13,188	321	27,424
Net cash (used in) provided by operating activities	(32,289)	124,678	109,091	67,135	268,615
Cash flows from investing activities:					
Cash paid for fixed assets	(27,895)	(22,148)	(46,246)	(63,271)	(159,560
Cash paid for investments	_	_	(1,000)		(1,000
Distributions from equity investees	_	73	_	_	73
Proceeds from sale of assets	_	1,296	_	2,006	3,302
Net cash used in investing activities	(27,895)	(20,779)	(47,246)	(61,265)	(157,185
Cash flows from financing activities:	(
Borrowings under long-term debt agreements	397,000	43.000	_	36,000	476,000
Repayments of long-term debt	(142,313)	(314,312)	(31,313)	(1,066,952)	(1,554,890
Payments for finance and capital lease liabilities	(935)	(1,154)	(742)	(573)	(3,404
Proceeds from initial public offering, net of issuance costs	(000)	(1,101)	(112)	936,041	936,041
Repurchase of equity		(105)	_		(105
Payment of contingent consideration	_	(250)	_	_	(250
Net cash provided by (used in) financing activities	253,752	(272,821)	(32,055)	(95,484)	(146,608
Net increase (decrease) in cash, cash equivalents and restricted cash	193,568	(168,922)	29,790	(89,614)	(35,178
Cash, cash equivalents and restricted cash at beginning of period	154,718	348,286	179,364	209,154	154,718
Cash, cash equivalents and restricted cash at end of period	\$ 348,286	\$ 179.364	\$ 209.154	\$ 119,540	\$ 119.540

RECONCILIATIONS OF NON-GAAP TO GAAP FINANCIAL MEASURES

The following information provides definitions and reconciliations of the non-GAAP financial measures presented in this earnings release to the most directly comparable financial measures calculated and presented in accordance with generally accepted accounting principles (GAAP). The company has provided this non-GAAP financial information, which is not calculated or presented in accordance with GAAP, as information supplemental and in addition to the financial measures presented in the earnings release that are calculated and presented in accordance with GAAP. Such non-GAAP financial measures should not be considered superior to, as a substitute for or alternative to, and should be considered in conjunction with, the GAAP financial measures presented in the earnings release may differ from similarly titled measures used by other companies.

Adjusted EBITDA

Adjusted EBITDA is considered a non-GAAP financial measure under the SEC's rules because it excludes certain charges included in net income (loss) calculated in accordance with GAAP. Management believes that Adjusted EBITDA is a meaningful measure to share with investors because it best allows comparison of the current period performance with that of the comparable period. In addition, Adjusted EBITDA affords investors a view of what management considers Petco's operating performance to be as well as the ability to make a more informed assessment of such operating performance as compared with that of the prior period.

Please see the company's 10-K filed on April 5, 2021, for additional information on the reconciliation of Net Income (Loss) Attributable to Class A and B-1 Common Stockholders to Adjusted EBITDA. The tables below reflect the calculation of Adjusted EBITDA for the thirteen weeks and trailing twelve months ended May 1, 2021 compared to the prior year quarter and twelve-month period ended May 2, 2020, respectively.

(In Thousands)	13 Week	s Ended
Reconciliation of Net Income (Loss) Attributable to Class A and B-1 Common Stockholders to Adjusted EBITDA	May 1, 2021	May 2, 2020
Net income (loss) attributable to Class A and B-1 common stockholders	\$ 7,560	\$ (31,168)
Add (deduct):		
Interest expense, net	20,508	60,624
Income tax expense (benefit)	2,679	(10,555)
Depreciation and amortization	41,607	43,567
Income from equity method investees	(2,425)	(332)
Loss on debt extinguishment and modification	20,838	_
Asset impairments and write offs	947	3,409
Equity-based compensation	11,604	2,305
Mexico joint venture EBITDA ¹	6,006	4,019
Store pre-opening expenses	4,029	1,908
Store closing expenses	1,103	1,027
Severance	818	3,084
Non-cash occupancy-related costs ²	1,139	7,200
Non-recurring costs ³	9,333	1,748
Adjusted EBITDA	\$ 125,746	\$ 86,836
Net sales	\$ 1,414,994	\$ 1,113,521
Net margin ⁴	0.5%	(2.8%)
Adjusted EBITDA Margin	8.9%	7.8%

(In Thousands)	Trailing Twelve Mon			
Reconciliation of Net Income (Loss) Attributable to Class A and B-1 Common Stockholders to Adjusted EBITDA	May 1, 2021	May 2, 2020		
Net income (loss) attributable to Class A and B-1 common stockholders	\$ 12,245	\$ (89,560)		
Add (deduct):				
Interest expense, net	178,314	248,915		
Income tax expense (benefit)	9,897	(33,699)		
Depreciation and amortization	172,876	171,593		
Income from equity method investees	(8,575)	(2,755)		
Loss on debt extinguishment and modification	38,387	_		
Goodwill & indefinite-lived intangible impairment	_	19,000		
Asset impairments and write offs	13,144	10,523		
Equity-based compensation	22,214	10,067		
Mexico joint venture EBITDA ¹	21,061	15,199		
Store pre-opening expenses	11,349	9,648		
Store closing expenses	7,858	4,914		
Severance	3,017	10,567		
Non-cash occupancy-related costs ²	13,179	30,911		
Non-recurring costs ³	28,292	8,328		
Adjusted EBITDA	\$ 523,258	\$ 413,651		
Net sales	\$ 5,221,675	\$ 4,450,878		
Net margin ⁴	0.2%	(2.0%)		
Adjusted EBITDA Margin	10.0%	9.3%		

Adjusted Net Income and Adjusted EPS

Adjusted Net Income and Adjusted diluted earnings per share attributable to Petco (Adjusted Net Income and Adjusted EPS respectively) are considered non-GAAP financial measures under the SEC's rules because they exclude certain amounts included in the net income (loss) attributable to common stockholders and diluted earnings per share attributable to Petco calculated in accordance with GAAP (net income (loss) and EPS respectively), the most directly comparable financial measures calculated in accordance with GAAP. Management believes that Adjusted Net Income and Adjusted EPS are meaningful measures to share with investors because they best allow comparison of the current period performance with that of the comparable period. In addition, Adjusted Net Income and Adjusted EPS afford investors a view of what management considers Petco's earnings performance to be as well as the ability to make a more informed assessment of such earnings performance with that of the prior period.

The tables below reflect the calculation of Adjusted Net Income (Loss) and Adjusted EPS for the thirteen weeks ended May 1, 2021 compared to the prior year quarter ended May 2, 2020.

(In Thousands, except per share amounts)	13 Weeks Ended							
Reconciliation of Diluted Income (Loss) per Share to Adjusted EPS	May 1, 2021			May 2, 2			,	
	A	Amount Per share		mount Per share Amount		Per	r share	
Net income (loss) attributable to common stockholders / diluted income (loss)								
per share	\$	7,560	\$	0.03	\$	(31,168)	\$	(0.15)
Add (deduct):								
Income tax expense (benefit)		2,679		0.01		(10,555)		(0.05)
Loss on debt extinguishment and modification		20,838		0.08		_		_
Asset impairments and write offs		947		0.00		3,409		0.02
Equity-based compensation		11,604		0.04		2,305		0.01
Store pre-opening expenses		4,029		0.02		1,908		0.01
Store closing expenses		1,103		0.00		1,027		0.01
Severance		818		0.00		3,084		0.01
Non-cash occupancy-related costs ²		1,139		0.01		7,200		0.03
Non-recurring costs ³		9,333		0.04		1,748		0.01
Adjusted pre-tax income (loss) / diluted earnings (loss) per share	\$	60,050	\$	0.23	\$	(21,042)	\$	(0.10)
Income tax expense (benefit) at 26% normalized tax rate		15,613		0.06		(5,471)		(0.03)
Adjusted Net Income (Loss) / Adjusted EPS	\$	44,437	\$	0.17	\$	(15,571)	\$	(0.07)

Free Cash Flow

Free Cash Flow is a non-GAAP financial measure that is calculated as net cash generated by operations less cash paid for fixed assets. Management believes that Free Cash Flow, which measures the ability to generate additional cash from business operations, is an important financial measure for use in evaluating the company's financial performance.

Although other companies report their Free Cash Flow, numerous methods exist for calculating a company's Free Cash Flow. As a result, the method used by Petco's management to calculate Free Cash Flow may differ from the methods used by other companies to calculate their Free Cash Flow.

The following table sets forth a reconciliation of Free Cash Flow to net cash provided by (used in) operating activities, which Petco believes to be the GAAP financial measure most directly comparable to Free Cash Flow. The table below reflects the calculation of Free Cash Flow for the thirteen weeks ended May 1, 2021 compared to the prior year quarter ended May 2, 2020.

(In Thousands)	13 Weeks	Ended
	May 1, 2021	May 2, 2020
Net cash provided by (used in) operating activities	\$ 115,002	\$ (32,289)
Cash paid for fixed assets	(47,351)	(27,895)
Free Cash Flow	\$ 67,651	\$ (60,184)

Net Debt

Net Debt is a non-GAAP financial measure that is calculated as the sum of current and non-current debt, less cash and cash equivalents. Management considers this adjustment useful because it reduces the volatility of total debt caused by fluctuations between cash paid against the company's revolving credit facility and cash held on hand in cash and cash equivalents.

Although other companies report their Net Debt, numerous methods exist for calculating a company's Net Debt. As a result, the method used by Petco's management to calculate Net Debt may differ from the methods used by other companies to calculate their Net Debt.

The following table sets forth a reconciliation of Net Debt, to total debt, which Petco believes to be the GAAP financial measure most directly comparable to Net Debt. The table below reflects the calculation of Net Debt as of the period ended May 1, 2021 compared to the prior year period ended May 2, 2020.

May 1, 2021		Μ	ay 2, 2020
\$	1,666,509	\$	2,647,461
			866,952
	16,409		15,504
	1,682,918		3,529,917
	(174,034)		(341,506)
\$	1,508,884	\$	3,188,411
\$	523,258	\$	413,651
	2.9x		7.7x
	\$	\$ 1,666,509 	\$ 1,666,509 \$ 16,409 1,682,918 (174,034) \$ 1,508,884 \$ 523,258 \$

Adjusted EBITDA, Adjusted Net Income and Adjusted EPS Footnotes

(1) Mexico joint venture EBITDA represents 50% of the entity's operating results for all periods, as adjusted to reflect the results on a basis comparable to Adjusted EBITDA. In the financial statements, this joint venture is accounted for as an equity method investment, and reported net of depreciation and income taxes. Because such a presentation would not reflect the adjustments made in the calculation of Adjusted EBITDA, we include the 50% interest in the company's Mexico joint venture on an Adjusted EBITDA basis to ensure consistency. The table below presents a reconciliation of Mexico joint venture net income to Mexico joint venture EBITDA.

(In Thousands)	13 Wee	ks Ended			
	May 1, 2021	May	/ 2, 2020		
Net income	\$ 4,849	\$	728		
Depreciation	3,400		3,154		
Income tax expense	2,780		1,295		
Foreign currency (gain) loss	(145)		1,557		
Interest expense, net	1,128		1,304		
EBITDA	\$ 12,012	\$	8,038		
50% of EBITDA	\$ 6,006	\$	4,019		

- (2) Non-cash occupancy-related costs include the difference between cash and straight-line rent for all periods. Beginning in fiscal 2019, in connection with our adoption of the lease accounting standard, favorable lease rights of \$125.2 million and unfavorable lease rights of \$30.8 million were reclassified from intangible assets and other long-term liabilities, respectively, to right-of-use lease assets and the related amortization is now included in non-cash occupancy costs. In addition to the reclassification, the amortization period of these lease right assets has decreased to align with the terms of the underlying right-of-use lease assets, thus resulting in an acceleration of expense compared to prior years. The overall adoption of the lease accounting standard did not have an impact on our Adjusted EBITDA, as this increase in addback was completely offset in other impacted lines such as lower depreciation and amortization, asset impairments and write-offs, and store closing expenses.
- (3) Non-recurring costs include: unrealized fair market value adjustments on non-operating investments; class action settlements and related legal fees; one-time consulting and other costs associated with our strategic transformation initiatives; discontinuation and liquidation costs; and costs related to the initial public offering. While we incurred significant costs associated with the COVID-19 pandemic during fiscal 2020, we have not classified any of these costs as non-recurring due to the uncertainty surrounding the pandemic's length and longterm impact on the macroeconomic operating environment.
- (4) We define net margin as net income (loss) attributable to Class A and B-1 common stockholders divided by net sales and Adjusted EBITDA margin as Adjusted EBITDA divided by net sales

HISTORICAL RECONCILIATION OF NON-GAAP TO GAAP FINANCIAL MEASURES

Adjusted EBITDA

(In Thousands)		13 Weel	ks Ended		Fiscal Year Ended
Reconciliation of Net (Loss) Income Attributable to Class A and B-1 Common Stockholders to Adjusted EBITDA	May 2, 2020	August 1, October 31, January 30, 2020 2020 2021		January 30, 2021	
Net (loss) income attributable to Class A and B-1 common stockholders	\$ (31,168)	\$ 7,441	\$ 3,403	\$ (6,159)	\$ (26,483)
Add (deduct):					
Interest expense, net	60,624	54,394	53,746	49,666	218,430
Income tax (benefit) expense	(10,555)	4,958	(7,940)	10,200	(3,337)
Depreciation and amortization	43,567	42,471	42,923	45,875	174,836
Income from equity method investees	(332)	(745)	(1,875)	(3,530)	(6,482)
Loss on debt extinguishment	_	_	_	17,549	17,549
Asset impairments and write offs	3,409	2,852	1,390	7,955	15,606
Equity-based compensation	2,305	2,312	2,847	5,451	12,915
Mexico joint venture EBITDA ¹	4,019	3,483	4,917	6,655	19,074
Store pre-opening expenses	1,908	1,477	3,625	2,218	9,228
Store closing expenses	1,027	2,609	2,311	1,835	7,782
Severance	3,084	331	344	1,524	5,283
Non-cash occupancy-related costs ²	7,200	5,969	3,920	2,151	19,240
Non-recurring costs ³	1,748	3,260	8,490	7,209	20,707
Adjusted EBITDA	\$ 86,836	\$ 130,812	\$ 118,101	\$ 148,599	\$ 484,348
Net sales	\$ 1,113,521	\$ 1,208,971	\$ 1,259,997	\$ 1,337,713	\$ 4,920,202
Net margin ⁴	(2.8%)	0.6%	0.3%	(0.5%)	(0.5%)
Adjusted EBITDA Margin	7.8%	10.8%	9.4%	11.1%	9.8%

(In Thousands)					Fiscal Year
		Ended			
Reconciliation of Net Loss Attributable to Class A and B-1	May 4,	August 3,	November 2,	February 1,	February 1,
Common Stockholders to Adjusted EBITDA	2019	2019	2019	2020	2020
Net loss attributable to Class A and B-1 common stockholders	\$ (37,481)	\$ (23,002)	\$ (28,219)	\$ (7,171)	\$ (95,873)
Add (deduct):					
Interest expense, net	64,392	64,510	63,119	60,662	252,683
Income tax benefit	(12,514)	(7,302)	(8,447)	(7,395)	(35,658)
Depreciation and amortization	45,518	40,096	43,986	43,944	173,544
(Income) loss from equity method investees	(18)	(420)	112	(2,115)	(2,441)
Goodwill & indefinite-lived intangible impairment	_	_	_	19,000	19,000
Asset impairments and write offs	4,757	927	3,572	2,615	11,871
Equity-based compensation	1,727	2,525	2,750	2,487	9,489
Mexico joint venture EBITDA ¹	3,047	3,100	3,293	4,787	14,227
Store pre-opening expenses	2,585	2,868	2,592	2,280	10,325
Store closing expenses	181	413	934	2,540	4,068
Severance	2,681	946	4,935	1,602	10,164
Non-cash occupancy-related costs ²	9,052	10,196	6,758	6,757	32,763
Non-recurring costs ³	13,805	255	4,399	1,926	20,385
Adjusted EBITDA	\$ 97,732	\$ 95,112	\$ 99,784	\$ 131,919	\$ 424,547
Net sales	\$ 1,097,157	\$ 1,095,632	\$ 1,093,069	\$ 1,148,656	\$ 4,434,514
Net margin ⁴	(3.4%)	(2.1%)	(2.6%)	(0.6%)	(2.2%)
Adjusted EBITDA Margin	8.9%	8.7%	9.1%	11.5%	9.6%

(1) Mexico joint venture EBITDA represents 50% of the entity's operating results for all periods, as adjusted to reflect the results on a basis comparable to Adjusted EBITDA. In the financial statements, this joint venture is accounted for as an equity method investment, and reported net of depreciation and income taxes. Because such a presentation would not reflect the adjustments made in the calculation of Adjusted EBITDA, we include the 50% interest in the company's Mexico joint venture on an Adjusted EBITDA basis to ensure consistency. The table below presents a reconciliation of Mexico joint venture net income to Mexico joint venture EBITDA.

(In Thousands)									Fise	cal Year
13 Weeks Ended							Ended			
		ay 2,	y 2, August 1,		October 31, 2020		January 30, 2021		January 30, 2021	
	2020 2020		2020							
Net income	\$	728	\$	2,384	\$	4,053	\$	7,060	\$	14,225
Depreciation		3,154		2,702		2,915		3,478		12,249
Income tax expense		1,295		1,129		2,103		1,702		6,229
Foreign currency loss (gain)		1,557		(295)		(395)		(163)		704
Interest expense, net		1,304		1,046		1,158		1,232		4,740
EBITDA	\$	8,038	\$	6,966	\$	9,834	\$	13,309	\$	38,147
50% of EBITDA	\$	4,019	\$	3,483	\$	4,917	\$	6,655	\$	19,074

(In Thousands)	13 Weeks Ended							Fiscal Yes Ended		
					ember 2, 2019	, February 1, 2020			ruary 1, 2020	
Net income	\$	1,559	\$	1,519	\$	1,482	\$	4,102	\$	8,662
Depreciation		2,560		2,674		2,788		3,276		11,298
Income tax expense		1,042		1,022		1,161		882		4,107
Foreign currency (gain) loss		(75)		(46)		39		(324)		(406)
Interest expense, net		1,008		1,031		1,116		1,638		4,793
EBITDA	\$	6,094	\$	6,200	\$	6,586	\$	9,574	\$	28,454
50% of EBITDA	\$	3,047	\$	3,100	\$	3,293	\$	4,787	\$	14,227

- (2) Non-cash occupancy-related costs include the difference between cash and straight-line rent for all periods. Beginning in fiscal 2019, in connection with our adoption of the lease accounting standard, favorable lease rights of \$125.2 million and unfavorable lease rights of \$30.8 million were reclassified from intangible assets and other long-term liabilities, respectively, to right-of-use lease assets and the related amortization is now included in non-cash occupancy costs. In addition to the reclassification, the amortization period of these lease right assets has decreased to align with the terms of the underlying right-of-use lease assets, thus resulting in an acceleration of expense compared to prior years. The overall adoption of the lease accounting standard did not have an impact on our Adjusted EBITDA, as this increase in addback was completely offset in other impacted lines such as lower depreciation and amortization, asset impairments and write-offs, and store closing expenses.
- (3) Non-recurring costs include: unrealized fair market value adjustments on non-operating investments; class action settlements and related legal fees; one-time consulting and other costs associated with our strategic transformation initiatives; discontinuation and liquidation costs; and costs related to the initial public offering. While we incurred significant costs associated with the COVID-19 pandemic during fiscal 2020, we have not classified any of these costs as non-recurring due to the uncertainty surrounding the pandemic's length and longterm impact on the macroeconomic operating environment.
- (4) We define net margin as net income (loss) attributable to Class A and B-1 common stockholders divided by net sales and Adjusted EBITDA margin as Adjusted EBITDA divided by net sales.